Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (20515)	5/11/1998 8:56:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

Here's a little more information on SRGN. Perhaps you will recognize the note poster, or who the posting is to. Message 2911568 Regards, Bob

To: squetch who wrote (20515)	5/11/1998 9:05:00 PM
From: tonyt	Read Replies (2) \| Respond to of 32384

Huge cash outlay and increased dilution to shareholders (for a company that, as you pointed out has 'Adverse Events Associated with Clinical Trials of Fusion Proteins'), but management seems confident (what do they know that we don't?). What does this do to Ligands 'burn rate'? Will they have enough cash or is another secondary possible?

To: squetch who wrote (20515)	5/11/1998 9:12:00 PM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 32384

Squetch, >Huh? Here is what SRGN lists as side-effects. Bear in mind 37% >withdrawal b/c of adverse events The last line doesn't instill >confidence in me. This is cancer. By far the most common side effect of non-treatment is an unpleasant demise.... Also, there is a real problem with cancer trials. They naturally tent to enroll patients whose entire systems are already severely compromised due to the disease and due to unsuccessfull prior treatments. Torben